ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2510

Impact of ANCA specificity on risk of severe infection occurrence in ANCA-associated vasculitis.
Abstract Number: 2686

Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Abstract Number: 0696

Impact of Autologous Stem Cell Transplantation on Cardiac Performance in Systemic Sclerosis
Abstract Number: 0072

Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
Abstract Number: 2267

Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Abstract Number: 1466

Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Abstract Number: 2344

Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
Abstract Number: 2363

Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Abstract Number: 1427

Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
Abstract Number: 1040

Impact of Clinical Pharmacist-Directed Patient Education on Medication Adherence and Clinical Outcomes in Patients with Inflammatory Arthritis
Abstract Number: 0640

Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
Abstract Number: 0476

Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence
Abstract Number: 1576

Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
Abstract Number: 0075

Impact of CXCL2 and IL-11 from Rheumatoid Arthritis Synovial Fibroblasts on Angiogenesis and Endothelial Cell Network Formation
Abstract Number: 0874

Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].